BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20703031)

  • 1. Antivascular endothelial growth factor in diabetic retinopathy.
    Iacono P; Battaglia Parodi M; Bandello F
    Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of diabetic retinopathy with anti-VEGF drugs.
    Waisbourd M; Goldstein M; Loewenstein A
    Acta Ophthalmol; 2011 May; 89(3):203-7. PubMed ID: 21044274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
    Nicholson BP; Schachat AP
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
    Jardeleza MS; Miller JW
    Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
    Bandello F; Cicinelli MV; Parodi MB
    Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenesis drugs in diabetic retinopathy.
    Jeganathan VS
    Curr Pharm Biotechnol; 2011 Mar; 12(3):369-72. PubMed ID: 20939797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Parravano M; Menchini F; Virgili G
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
    Ollendorf DA; Colby JA; Pearson SD
    Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
    Salam A; Mathew R; Sivaprasad S
    Acta Ophthalmol; 2011 Aug; 89(5):405-11. PubMed ID: 21294854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for diabetic retinopathy.
    Arevalo JF; Garcia-Amaris RA
    Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.